Clinical Trials Logo

Keratitis clinical trials

View clinical trials related to Keratitis.

Filter by:

NCT ID: NCT04552730 Completed - Clinical trials for Neurotrophic Keratitis

Nerve Growth Factor for the Treatment of Cornea Disease

Start date: October 14, 2020
Phase:
Study type: Observational

To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.

NCT ID: NCT04492878 Completed - Dry Eye Clinical Trials

Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment

Start date: February 4, 2020
Phase: Phase 4
Study type: Interventional

The proposed study is a prospective, open-label, unicentric, phase IV clinical trial. This study is design to find new efficacy biomarkers for IKERVIS® (1mg/mL ciclosporin) eye drops after 1 and 3 month after initiation of therapy. Additionally, this study intends to investigate whether IKERVIS® will help patients to better overcome situations of desiccating stress by exposing them to an adverse controlled environment (ACE) and analyzing both clinical and molecular parameters.

NCT ID: NCT04485546 Completed - Clinical trials for Neurotrophic Keratitis

Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis

DEFENDO
Start date: September 9, 2020
Phase: Phase 4
Study type: Interventional

This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).

NCT ID: NCT04420429 Completed - Clinical trials for Endothelial Dysfunction

The Effect Of Preoperative Parameters On Success After DMEK Surgery

Start date: June 1, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to evaluate the effect of preoperative parameters on surgical results in Descemet Membrane Endothelial Keratoplasty (DMEK) surgery.

NCT ID: NCT04383431 Completed - Clinical trials for Infectious Keratitis

Cross-linking as Treatment in Infectious Keratitis

Start date: June 2, 2020
Phase: N/A
Study type: Interventional

To compare between SCXL and ACXL for treatment of infectious keratitis

NCT ID: NCT04375852 Completed - Clinical trials for Autoimmune Polyglandular Syndrome Type I

Tyrosine Hydroxylase Antibody Levels in Autoimmune Polyglandular Syndrome Type 1 Associated Keratitis

Start date: January 1, 2014
Phase: N/A
Study type: Interventional

Tyrosine hydroxylase autoantibodies impair sympathetic innervation leading to keratitis. In this study, the investigators have shown the significant association between severity of keratitis and presence of tyrosine hydroxylase autoantibodies.

NCT ID: NCT04276558 Completed - Clinical trials for Neurotrophic Keratitis

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Start date: October 13, 2020
Phase: Phase 2
Study type: Interventional

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.

NCT ID: NCT04213313 Completed - Clinical trials for Infectious Keratitis

Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis

ABSOSASAPOIK
Start date: October 1, 2016
Phase:
Study type: Observational [Patient Registry]

This study explores the association between single nucleotide polymorphism (Met11Thr) of surfactant protein D(SP-D) and susceptibility and prognosis of infectious keratitis.Met11Thr of SP-D of patients with keratitis and normal controls were compared.Allele and genotype frequencies of patients with keratitis and normal controls were determined by polymerase chain reaction with sequence specific primers(PCR-SSPs) .SP-D gene polymorphism of patients with keratitis and normal controls was detected by Sanger sequencing

NCT ID: NCT04169061 Completed - Keratitis Clinical Trials

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Start date: November 13, 2019
Phase: Phase 4
Study type: Interventional

We will need about 36 participants for this study. Volunteers might be able to participate if: - they have bad noninfectious keratitis - early treatments failed or were not well tolerated Participants will be in the study for about 22 weeks: - 4 weeks for tests to see if the study might be good for them - 12 weeks of treatment with Acthar gel - 4 weeks to wean off Acthar gel and follow-up with the doctor

NCT ID: NCT04144413 Completed - Clinical trials for Dry Eye Disease With Severe Keratitis

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Start date: May 31, 2019
Phase: Phase 3
Study type: Interventional

The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED) patients with severe keratitis receiving Ikervis® (1mg/mL ciclosporin) eye drops administered once daily